Dual CAR T-Cell Platform for Soluble Ligand Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches, such as CAR-T cell therapies, are limited in targeting soluble ligands in the tumor microenvironment, leading to 'on-target off-tumour' toxicity and lack of specificity, as they primarily recognize membrane-bound antigens, failing to effectively harness the potential of soluble antigens like chemokines and cytokines for cancer treatment.
Innovation Solution
Development of a dual CAR platform where two CARs recognize distinct epitopes on the same soluble ligand, shifting the signaling mechanism from size-based exclusion to aggregation, allowing for targeted activation of T-cells in the presence of both membrane-bound and soluble antigens, thereby reducing off-tumour toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-T cells are designed to recognize membrane-bound antigens, then T-cell activation and cancer cell killing are achieved, but off-tumour toxicity occurs due to lack of specificity for soluble ligands
Solution Approach 1:
The invention divides the targeting function into two separate CARs: one CAR recognizes a membrane-bound antigen on tumor cells, while the other CAR recognizes a soluble ligand in the tumor microenvironment. This segmentation allows the system to distinguish tumor cells (which have both membrane antigen and secrete soluble ligand) from normal cells (which have only the membrane antigen), thereby reducing off-tumour toxicity while maintaining reliable targeting
Solution Approach 2:
The invention changes the activation parameter from single-antigen recognition to dual-antigen recognition. T-cell activation occurs only when both CARs are simultaneously engaged - one by membrane-bound antigen and the other by soluble ligand. This parameter change creates a more specific activation condition that reduces harmful off-target effects while maintaining effective tumor targeting
2Reliability
If CARs are designed to recognize soluble ligands, then specificity for tumor microenvironment is improved, but T-cell activation signaling is insufficient with single CAR recognition
Solution Approach 1:
The invention merges two recognition systems into a unified T-cell activation platform. One CAR recognizes the membrane-bound antigen while the other recognizes the soluble ligand. Both recognition events are merged through spatial proximity requirements, ensuring that T-cell activation signaling is powered by combined recognition of both antigens, thereby providing sufficient activation power while maintaining high specificity for the tumor microenvironment
3Reliability
If dual CAR platform is implemented, then specificity and reduced toxicity are achieved, but system complexity increases
Solution Approach 1:
The invention implements a universal dual CAR platform that can be adapted to different tumor types by changing the specific antigen targets. The same basic architecture - two CARs with complementary specificity requirements - can target different tumor microenvironments by swapping the antigen recognition domains. This multi-functionality reduces the need for completely different system designs for different cancers, thereby managing complexity while maintaining high targeting precision across multiple applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise targeting of cancer cells by aggregating CARs on the surface of T-cells in response to soluble ligands, enhancing specificity and reducing harm to normal tissues, thus improving the therapeutic index of CAR-T cell therapies.
Implementation Method 1
the presence of ligand causes aggregation of ligand-associated CARs on the surface of the cell
Implementation Method 2
the first and second CARs bind different epitopes on the same ligand
Data Source
AI summary
The present invention provides a cell which comprises a first chimeric antigen receptor (CAR) and a second CAR, wherein the first and second CARs bind different epitopes on the same ligand. The cell may be used in a method for treating a disease, such as cancer.